Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volpe, M.
Right arrow Articles by Rubattu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volpe, M.
Right arrow Articles by Rubattu, S.
J Am Soc Nephrol 13:S173-S178, 2002
© 2002 American Society of Nephrology

The Renin-Angiotensin System as a Risk Factor and Therapeutic Target for Cardiovascular and Renal Disease

Massimo Volpe*,{dagger}, Carmine Savoia*, Paola De Paolis{dagger}, Beata Ostrowska*, David Tarasi* and Speranza Rubattu{dagger}

*Department of Experimental Medicine and Pathology, University of Rome "La Sapienza," Italy; and {dagger}IRCSS Istituto Neurologico Mediterraneo "Neuromed", Località Camerelle, Pozzilli (Is), Italy.

Correspondence to Prof. Massimo Volpe, Department of Experimental Medicine and Pathology, V.le Regina Elena, 324, 00161 Rome Italy. Phone/Fax: 39-06-49970723;

ABSTRACT. The renin-angiotensin system (RAS) plays an important homeostatic role in BP regulation, water and salt balance, and tissue growth control under physiologic conditions. On the other hand, a pivotal involvement of the RAS in the pathophysiology of cardiovascular and renal disease is extensively supported by both basic and clinical evidence. In particular, it is today recognized that angiotensin II (AngII), the biologic effector of the RAS, may prompt a number of relevant structural and functional abnormalities through the activation of a complex of cellular effects mostly mediated via its binding with the AT1 subtype receptors. The key role of these AngII-linked mechanisms of disease is strongly corroborated by large interventional studies. In fact, pharmacologic interference with RAS activity, by both preventing AngII formation with angiotensin-converting enzyme inhibitors or antagonizing its binding to cell membrane receptors by selective antagonists, is associated with highly beneficial outcomes in major disease conditions (hypertension, diabetes, renal failure, heart failure, myocardial infarction, stroke, and others). This article briefly reviews the current views on the biologic organization of RAS evidence supporting a pathogenic role of the RAS activity in promoting cardiac, vascular, and renal disease, and finally provides the basis for considering inhibition of RAS activity a major target for therapeutic interventions in these conditions. E-mail: volpema@uniroma1.it




This article has been cited by other articles:


Home page
 HypertensionHome page
T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, H. Kitabata, T. Tanimoto, Y. Muragaki, S. Mochizuki, M. Goto, et al.
Renin Inhibitor Aliskiren Improves Impaired Nitric Oxide Bioavailability and Protects Against Atherosclerotic Changes
Hypertension, September 1, 2008; 52(3): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. J Brown
Renin: friend or foe?
Heart, September 1, 2007; 93(9): 1026 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Persson, P. Rossing, P. Hovind, C. D.A. Stehouwer, C. Schalkwijk, L. Tarnow, and H.-H. Parving
Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy
Diabetes, December 1, 2006; 55(12): 3550 - 3555.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. C. Liebau, D. Lang, J. Bohm, N. Endlich, M. J. Bek, I. Witherden, P. W. Mathieson, M. A. Saleem, H. Pavenstadt, and K.-G. Fischer
Functional expression of the renin-angiotensin system in human podocytes
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F710 - F719.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J. Main
Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death
Heart, April 1, 2005; 91(4): 548 - 552.
[Full Text] [PDF]

Home page
 CirculationHome page
G. L. Smith, M. G. Shlipak, E. P. Havranek, F. A. Masoudi, W. M. McClellan, J. M. Foody, S. S. Rathore, and H. M. Krumholz
Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites
Circulation, March 15, 2005; 111(10): 1270 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Stegbauer, V. Oberhauser, O. Vonend, and L. C. Rump
Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats
Cardiovasc Res, February 1, 2004; 61(2): 352 - 359.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhou, W. P. Dirksen, G. J. Babu, and M. Periasamy
Differential vasoconstrictions induced by angiotensin II: role of AT1 and AT2 receptors in isolated C57BL/6J mouse blood vessels
Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2797 - H2803.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673